 Christina Coughlan
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 7 | 2023 | 436 | 1.650 |
Why?
| | Exosomes | 3 | 2023 | 91 | 0.900 |
Why?
| | Astrocytes | 4 | 2022 | 162 | 0.890 |
Why?
| | White Matter | 2 | 2023 | 102 | 0.860 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2022 | 134 | 0.820 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.800 |
Why?
| | Sialyltransferases | 8 | 1999 | 13 | 0.770 |
Why?
| | Amyloid beta-Protein Precursor | 5 | 2022 | 54 | 0.740 |
Why?
| | Healthy Aging | 1 | 2021 | 17 | 0.740 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 79 | 0.730 |
Why?
| | Memory, Episodic | 1 | 2021 | 38 | 0.720 |
Why?
| | Ultracentrifugation | 1 | 2020 | 47 | 0.720 |
Why?
| | Saccharomyces cerevisiae | 5 | 2022 | 477 | 0.630 |
Why?
| | Amyloid beta-Peptides | 5 | 2022 | 189 | 0.550 |
Why?
| | Nanoparticles | 1 | 2020 | 313 | 0.550 |
Why?
| | Peptide Fragments | 3 | 2022 | 668 | 0.510 |
Why?
| | Proteomics | 1 | 2020 | 843 | 0.480 |
Why?
| | Dexamethasone | 7 | 1999 | 317 | 0.440 |
Why?
| | Down Syndrome | 4 | 2022 | 338 | 0.400 |
Why?
| | Neurons | 6 | 2022 | 1280 | 0.390 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2021 | 47 | 0.350 |
Why?
| | Sialoglycoproteins | 3 | 1997 | 158 | 0.300 |
Why?
| | Herpes Zoster | 2 | 2023 | 331 | 0.300 |
Why?
| | Protein Folding | 3 | 2005 | 239 | 0.300 |
Why?
| | Neuroblastoma | 3 | 1999 | 132 | 0.270 |
Why?
| | Stroke | 3 | 2023 | 1019 | 0.260 |
Why?
| | Protein Conformation | 2 | 2005 | 811 | 0.250 |
Why?
| | Aprotinin | 1 | 2004 | 9 | 0.230 |
Why?
| | Vacuoles | 1 | 2004 | 33 | 0.230 |
Why?
| | Proteome | 1 | 2007 | 339 | 0.230 |
Why?
| | Glucocorticoids | 3 | 1999 | 532 | 0.230 |
Why?
| | Recombinant Proteins | 2 | 2007 | 1233 | 0.220 |
Why?
| | Neurodegenerative Diseases | 1 | 2005 | 91 | 0.220 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 79 | 0.210 |
Why?
| | Protein Processing, Post-Translational | 4 | 2011 | 399 | 0.200 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 32 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 62 | 0.200 |
Why?
| | Disease | 1 | 2003 | 85 | 0.200 |
Why?
| | Endoplasmic Reticulum | 1 | 2004 | 234 | 0.200 |
Why?
| | Virion | 1 | 2022 | 73 | 0.190 |
Why?
| | Retinal Drusen | 1 | 2021 | 25 | 0.190 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 58 | 0.190 |
Why?
| | Aldosterone | 4 | 1999 | 42 | 0.190 |
Why?
| | Arteritis | 1 | 2021 | 27 | 0.190 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2022 | 63 | 0.180 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2021 | 106 | 0.180 |
Why?
| | Cell Polarity | 1 | 2021 | 131 | 0.180 |
Why?
| | Myelitis | 1 | 2022 | 88 | 0.180 |
Why?
| | Chemical Precipitation | 1 | 2020 | 37 | 0.180 |
Why?
| | Neuromuscular Diseases | 1 | 2022 | 89 | 0.180 |
Why?
| | Enterovirus D, Human | 1 | 2022 | 72 | 0.180 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 83 | 0.180 |
Why?
| | Amyloid | 1 | 2021 | 80 | 0.180 |
Why?
| | Receptors, Chemokine | 1 | 2000 | 43 | 0.170 |
Why?
| | Biomarkers | 5 | 2023 | 3414 | 0.170 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2020 | 19 | 0.170 |
Why?
| | Animals | 19 | 2023 | 31761 | 0.170 |
Why?
| | Macular Degeneration | 1 | 2021 | 152 | 0.170 |
Why?
| | Chemokine CCL2 | 1 | 2000 | 105 | 0.170 |
Why?
| | Brain Ischemia | 1 | 2023 | 299 | 0.170 |
Why?
| | Enterovirus Infections | 1 | 2022 | 160 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 3 | 1999 | 498 | 0.160 |
Why?
| | Kidney | 2 | 2015 | 1184 | 0.160 |
Why?
| | Humans | 25 | 2023 | 114716 | 0.150 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2017 | 8 | 0.150 |
Why?
| | Cell Communication | 2 | 2000 | 279 | 0.150 |
Why?
| | N-Acetylneuraminic Acid | 2 | 1999 | 8 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 273 | 0.140 |
Why?
| | Proteostasis Deficiencies | 1 | 2017 | 6 | 0.140 |
Why?
| | tau Proteins | 1 | 2017 | 68 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1997 | 211 | 0.140 |
Why?
| | Aneuploidy | 1 | 2017 | 85 | 0.140 |
Why?
| | Tumor Cells, Cultured | 5 | 2000 | 854 | 0.140 |
Why?
| | Trisomy | 1 | 2017 | 68 | 0.140 |
Why?
| | Aged, 80 and over | 4 | 2023 | 6346 | 0.140 |
Why?
| | Cystic Fibrosis | 1 | 2005 | 955 | 0.130 |
Why?
| | Brain Chemistry | 1 | 1996 | 116 | 0.130 |
Why?
| | Proteins | 1 | 2021 | 912 | 0.130 |
Why?
| | Models, Biological | 1 | 2003 | 1630 | 0.130 |
Why?
| | Isoenzymes | 1 | 1996 | 285 | 0.120 |
Why?
| | Aged | 7 | 2023 | 19079 | 0.120 |
Why?
| | Brain | 4 | 2023 | 2369 | 0.120 |
Why?
| | Oxidative Stress | 2 | 2021 | 1084 | 0.110 |
Why?
| | Molecular Sequence Data | 5 | 2015 | 2791 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 219 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2017 | 323 | 0.110 |
Why?
| | Signal Transduction | 3 | 2021 | 4521 | 0.100 |
Why?
| | Nerve Tissue Proteins | 1 | 1996 | 529 | 0.100 |
Why?
| | Enzyme Induction | 3 | 1997 | 84 | 0.100 |
Why?
| | Glioma | 1 | 1995 | 294 | 0.100 |
Why?
| | Amino Acid Sequence | 3 | 2015 | 1988 | 0.100 |
Why?
| | Transcription Factor AP-2 | 1 | 2011 | 81 | 0.090 |
Why?
| | Palliative Care | 1 | 2017 | 641 | 0.090 |
Why?
| | Ethanol | 1 | 2015 | 548 | 0.090 |
Why?
| | Rats | 7 | 1999 | 4943 | 0.090 |
Why?
| | Caregivers | 1 | 2017 | 714 | 0.090 |
Why?
| | Membrane Transport Proteins | 1 | 2011 | 138 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 977 | 0.090 |
Why?
| | Apoptosis | 2 | 2017 | 2369 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2096 | 0.090 |
Why?
| | Adrenalectomy | 4 | 1999 | 60 | 0.090 |
Why?
| | Mitochondria | 1 | 2015 | 751 | 0.090 |
Why?
| | Middle Aged | 5 | 2023 | 26746 | 0.080 |
Why?
| | Receptors, Nicotinic | 1 | 2011 | 274 | 0.080 |
Why?
| | Alcoholism | 1 | 2015 | 714 | 0.080 |
Why?
| | Herpesvirus 3, Human | 2 | 2023 | 378 | 0.080 |
Why?
| | Liver | 1 | 1996 | 1631 | 0.080 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2011 | 333 | 0.080 |
Why?
| | Glycosylation | 3 | 1999 | 130 | 0.070 |
Why?
| | Schizophrenia | 1 | 2011 | 415 | 0.070 |
Why?
| | Female | 7 | 2023 | 59486 | 0.070 |
Why?
| | Male | 7 | 2023 | 55558 | 0.070 |
Why?
| | Drug Stability | 1 | 2007 | 151 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2011 | 1022 | 0.070 |
Why?
| | Mutation | 4 | 2017 | 3349 | 0.070 |
Why?
| | DNA Primers | 1 | 2007 | 514 | 0.070 |
Why?
| | Golgi Apparatus | 2 | 2004 | 89 | 0.070 |
Why?
| | Polysaccharides | 2 | 2004 | 78 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2023 | 3004 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 3890 | 0.060 |
Why?
| | Cognition | 2 | 2022 | 983 | 0.060 |
Why?
| | Mice | 7 | 2022 | 14916 | 0.060 |
Why?
| | Hippocampus | 2 | 2022 | 695 | 0.060 |
Why?
| | Calnexin | 1 | 2004 | 3 | 0.060 |
Why?
| | Kinetics | 2 | 1998 | 1550 | 0.060 |
Why?
| | Centrifugation, Density Gradient | 1 | 2004 | 40 | 0.060 |
Why?
| | Mass Spectrometry | 1 | 2007 | 633 | 0.060 |
Why?
| | Cycloheximide | 1 | 2004 | 54 | 0.060 |
Why?
| | Concanavalin A | 1 | 2004 | 75 | 0.060 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 49 | 0.060 |
Why?
| | Precipitin Tests | 1 | 2004 | 88 | 0.060 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 42 | 0.060 |
Why?
| | Cysteine Endopeptidases | 1 | 2004 | 60 | 0.060 |
Why?
| | Multienzyme Complexes | 1 | 2004 | 64 | 0.060 |
Why?
| | Sucrose | 1 | 2004 | 91 | 0.060 |
Why?
| | Disulfides | 1 | 2004 | 90 | 0.060 |
Why?
| | Base Sequence | 1 | 2007 | 2118 | 0.060 |
Why?
| | Intermediate Filaments | 1 | 2023 | 46 | 0.050 |
Why?
| | Fungal Proteins | 1 | 2004 | 119 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2003 | 58 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 43 | 0.050 |
Why?
| | Carbohydrate Sequence | 3 | 1999 | 23 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 62 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 83 | 0.050 |
Why?
| | Plasmids | 1 | 2004 | 345 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 12 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2003 | 92 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2321 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 77 | 0.050 |
Why?
| | Densitometry | 1 | 2022 | 29 | 0.050 |
Why?
| | Chemokines | 1 | 2003 | 213 | 0.050 |
Why?
| | Virus Internalization | 1 | 2022 | 40 | 0.050 |
Why?
| | Polymerization | 1 | 2022 | 119 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 140 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 797 | 0.050 |
Why?
| | Catalysis | 1 | 2022 | 292 | 0.050 |
Why?
| | Plasma | 1 | 2023 | 210 | 0.050 |
Why?
| | Lectins | 2 | 1998 | 43 | 0.050 |
Why?
| | Cattle | 1 | 2004 | 921 | 0.050 |
Why?
| | Neuroimaging | 1 | 2023 | 248 | 0.050 |
Why?
| | Interneurons | 1 | 2022 | 96 | 0.050 |
Why?
| | Organoids | 1 | 2021 | 74 | 0.050 |
Why?
| | Receptors, HIV | 1 | 2000 | 23 | 0.050 |
Why?
| | Retina | 1 | 2003 | 263 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 225 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2021 | 257 | 0.050 |
Why?
| | Immune System | 1 | 2022 | 173 | 0.050 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 286 | 0.050 |
Why?
| | Teratocarcinoma | 1 | 2000 | 2 | 0.040 |
Why?
| | Receptors, Dopamine D2 | 1 | 2000 | 86 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2021 | 80 | 0.040 |
Why?
| | Thrombosis | 1 | 2023 | 297 | 0.040 |
Why?
| | Intracellular Space | 1 | 2020 | 68 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 350 | 0.040 |
Why?
| | Extracellular Space | 1 | 2020 | 117 | 0.040 |
Why?
| | Acyclovir | 1 | 2020 | 100 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2020 | 73 | 0.040 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 182 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1999 | 27 | 0.040 |
Why?
| | Cell Line | 2 | 2022 | 2639 | 0.040 |
Why?
| | Nicotine | 1 | 2021 | 265 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 536 | 0.040 |
Why?
| | DNA, Viral | 1 | 2021 | 350 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 675 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2011 | 2557 | 0.040 |
Why?
| | Genotype | 1 | 2004 | 1773 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2000 | 192 | 0.040 |
Why?
| | Peptides | 1 | 2004 | 848 | 0.040 |
Why?
| | Protein Binding | 1 | 2004 | 1896 | 0.040 |
Why?
| | Calcium Signaling | 1 | 2000 | 213 | 0.040 |
Why?
| | Nervous System | 1 | 1998 | 63 | 0.040 |
Why?
| | Asialoglycoproteins | 1 | 1997 | 1 | 0.040 |
Why?
| | Fetuins | 1 | 1997 | 1 | 0.040 |
Why?
| | Cytidine Monophosphate N-Acetylneuraminic Acid | 1 | 1997 | 3 | 0.040 |
Why?
| | alpha-Fetoproteins | 1 | 1997 | 31 | 0.040 |
Why?
| | Homozygote | 1 | 2017 | 187 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 4710 | 0.040 |
Why?
| | Gene Dosage | 1 | 2017 | 134 | 0.040 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2017 | 31 | 0.040 |
Why?
| | Tretinoin | 1 | 1998 | 125 | 0.040 |
Why?
| | Heterozygote | 1 | 2017 | 251 | 0.040 |
Why?
| | Carbohydrate Conformation | 1 | 1996 | 15 | 0.030 |
Why?
| | Glycoproteins | 1 | 1998 | 304 | 0.030 |
Why?
| | Oligosaccharides | 1 | 1996 | 46 | 0.030 |
Why?
| | Parietal Lobe | 1 | 1996 | 41 | 0.030 |
Why?
| | Fetus | 1 | 2000 | 699 | 0.030 |
Why?
| | Glutathione Reductase | 1 | 2015 | 21 | 0.030 |
Why?
| | Peroxiredoxins | 1 | 2015 | 23 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 354 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 385 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2015 | 94 | 0.030 |
Why?
| | Brain Stem | 1 | 1996 | 101 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1998 | 252 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2017 | 582 | 0.030 |
Why?
| | Acetylation | 1 | 2015 | 211 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2015 | 156 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 413 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 646 | 0.030 |
Why?
| | Aldehydes | 1 | 2015 | 142 | 0.030 |
Why?
| | Cytokines | 1 | 2022 | 1843 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1998 | 1699 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 2973 | 0.030 |
Why?
| | Cerebellum | 1 | 1996 | 200 | 0.030 |
Why?
| | Glutathione | 1 | 2015 | 300 | 0.030 |
Why?
| | Time Factors | 1 | 2004 | 6124 | 0.030 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 305 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2017 | 1951 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 3542 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 1995 | 385 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2015 | 446 | 0.030 |
Why?
| | Qualitative Research | 1 | 2017 | 935 | 0.030 |
Why?
| | Amino Acids | 1 | 2015 | 448 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2481 | 0.020 |
Why?
| | SEC Translocation Channels | 1 | 2011 | 10 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4406 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2011 | 96 | 0.020 |
Why?
| | Protein Stability | 1 | 2011 | 157 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 345 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 176 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2011 | 291 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 562 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 396 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 543 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 9089 | 0.020 |
Why?
| | DNA Methylation | 1 | 2011 | 496 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 1895 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1133 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12513 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1316 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 17808 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 2725 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7935 | 0.010 |
Why?
| | Adult | 2 | 2023 | 30543 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2003 | 60 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2003 | 119 | 0.010 |
Why?
| | Chick Embryo | 1 | 2003 | 122 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2003 | 74 | 0.010 |
Why?
| | Nerve Growth Factors | 1 | 2003 | 71 | 0.010 |
Why?
| | Receptors, CXCR4 | 1 | 2003 | 78 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2003 | 77 | 0.010 |
Why?
| | Cell Count | 1 | 2003 | 305 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2003 | 225 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 130 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 278 | 0.010 |
Why?
| | Apelin Receptors | 1 | 2000 | 3 | 0.010 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2000 | 5 | 0.010 |
Why?
| | Apelin | 1 | 2000 | 8 | 0.010 |
Why?
| | Adipokines | 1 | 2000 | 42 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2000 | 75 | 0.010 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2000 | 70 | 0.010 |
Why?
| | Cell Survival | 1 | 2003 | 1021 | 0.010 |
Why?
| | Primates | 1 | 2000 | 111 | 0.010 |
Why?
| | Swainsonine | 1 | 1999 | 1 | 0.010 |
Why?
| | 1-Deoxynojirimycin | 1 | 1999 | 1 | 0.010 |
Why?
| | Mannosidases | 1 | 1999 | 4 | 0.010 |
Why?
| | Neuraminidase | 1 | 1999 | 22 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 285 | 0.010 |
Why?
| | Phosphorylation | 1 | 2003 | 1571 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2000 | 350 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 870 | 0.010 |
Why?
| | Biological Transport | 1 | 1999 | 372 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 493 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2000 | 1151 | 0.010 |
Why?
| | Pituitary Neoplasms | 1 | 1999 | 157 | 0.010 |
Why?
| | Solubility | 1 | 1998 | 224 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1151 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2003 | 2582 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2000 | 696 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 768 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2000 | 1270 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1745 | 0.010 |
Why?
| | Aging | 1 | 1994 | 1620 | 0.000 |
Why?
|
|
Coughlan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|